Kodiak Sciences Inc(KOD)stock report

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.

Finance:
Q3 2019(9/30/19): Cash 60.60M. Loss 23.61M

EPS and Sales:
https://finance.yahoo.com/quote/KOD/financials?p=KOD

Date EPS % last year % last quarter
2018.12.31 -2.77 25.54% -19.71%
2019.3.31 -0.21 81.90% 92.42%
2019.6.30 -0.52 75.36% -10.00%
2019.9.30 -0.85 75.36% -63.46%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=KOD&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/KOD/institutional-ownership/

2019.12.13:
Total institutions: 76,no change
Shares hold: 25049k shares. no change
shares% hold: 67.59%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/KOD/price-targe

Leave a Reply